In this article:

Vor Biopharma (VOR) Receives a Hold from Goldman Sachs

In this article:
In this article:

Goldman Sachs analyst Andrea Tan maintained a Hold rating on Vor Biopharma (VORResearch Report) today and set a price target of $4.00. The company’s shares closed last Tuesday at $4.15, close to its 52-week low of $4.01.

According to TipRanks.com, Tan has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -34.5% and a 0.0% success rate. Tan covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Codiak BioSciences, and Kodiak Sciences.

Vor Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $23.57.

See today’s best-performing stocks on TipRanks >>

Based on Vor Biopharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $18.25 million. In comparison, last year the company had a GAAP net loss of $13.72 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.

Read More on VOR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed